The Lynx Group

Keeping Cost Out of the Drug Approval Debate



The FDA has a regulatory function, which is probably best kept without looking at the costs of the medicines. The role is probably best for an independent HTA organization, like NICE. In Europe, the role of the EMA and of the HTA organization are 2 separate things, and that model works very well there.

Related Articles

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.

I'd like to recieve: